Found: 14
Select item for more details and to access through your institution.
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.
- Published in:
- PLoS ONE, 2024, v. 19, n. 1, p. 1, doi. 10.1371/journal.pone.0294590
- By:
- Publication type:
- Article
Postoperative bleeding after percutaneous transhepatic gallbladder drainage and aspiration in patients receiving antithrombotic therapy.
- Published in:
- PLoS ONE, 2023, v. 18, n. 8, p. 1, doi. 10.1371/journal.pone.0288463
- By:
- Publication type:
- Article
Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis.
- Published in:
- Hepatology Research, 2023, v. 53, n. 4, p. 301, doi. 10.1111/hepr.13868
- By:
- Publication type:
- Article
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 10, p. 824, doi. 10.1111/hepr.13806
- By:
- Publication type:
- Article
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma.
- Published in:
- Hepatology Research, 2022, v. 52, n. 7, p. 630, doi. 10.1111/hepr.13771
- By:
- Publication type:
- Article
Sodium taurocholate cotransporting polypeptide inhibition efficiently blocks hepatitis B virus spread in mice with a humanized liver.
- Published in:
- Scientific Reports, 2016, p. 27782, doi. 10.1038/srep27782
- By:
- Publication type:
- Article
Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral.
- Published in:
- Cancers, 2023, v. 15, n. 2, p. 463, doi. 10.3390/cancers15020463
- By:
- Publication type:
- Article
Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy.
- Published in:
- Cancers, 2022, v. 14, n. 14, p. N.PAG, doi. 10.3390/cancers14143367
- By:
- Publication type:
- Article
Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy.
- Published in:
- Cancers, 2022, v. 14, n. 4, p. 883, doi. 10.3390/cancers14040883
- By:
- Publication type:
- Article
Prognostic impact of worsening of esophageal varices after balloon‐occluded retrograde transvenous obliteration.
- Published in:
- Journal of Gastroenterology & Hepatology, 2022, v. 37, n. 6, p. 1148, doi. 10.1111/jgh.15853
- By:
- Publication type:
- Article
Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels.
- Published in:
- PLoS ONE, 2020, v. 15, n. 7, p. 1, doi. 10.1371/journal.pone.0235573
- By:
- Publication type:
- Article
Persistent hepatocyte apoptosis promotes tumorigenesis from diethylnitrosamine-transformed hepatocytes through increased oxidative stress, independent of compensatory liver regeneration.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-83082-7
- By:
- Publication type:
- Article
Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis.
- Published in:
- PLoS ONE, 2022, v. 17, n. 12, p. 1, doi. 10.1371/journal.pone.0279416
- By:
- Publication type:
- Article
Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C who achieved a sustained virological response through direct‐acting antiviral agents among the working population in Japan.
- Published in:
- JGH Open, 2022, v. 6, n. 6, p. 395, doi. 10.1002/jgh3.12745
- By:
- Publication type:
- Article